Biosimilar Rituximab (Redditux) Added to CHOP Chemotherapy for De Novo Diffuse Large B-Cell Lymphoma Patients: Real-Life Single-Center Experience

OBJECTIVE: Redditux(®) (RED), as a biosimilar rituximab, was approved in Turkey for all indications of the original Mabthera(®) (MAB) in March 2018. The aim of our study was to evaluate the efficacy and safety of RED in de novo diffuse large B-cell lymphoma. MATERIALS AND METHODS: Fifty-one patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Özbalak, Murat, Güzel Mastanzade, Metban, Özlük, Özden, Tiryaki, Tarık Onur, Erdem, Simge, Özbalak, Ezgi Pınar, Elverdi, Tuğrul, Yönal Hindilerden, İpek, Altay, Ali Yılmaz, Yeğen, Gülçin, Eşkazan, Ahmet Emre, Ar, Muhlis Cem, Yenerel, Mustafa Nuri, Soysal, Teoman, Nalçacı, Meliha, Ferhanoğlu, Burhan, Kalayoğlu Beşışık, Sevgi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Galenos Publishing 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9727716/
https://www.ncbi.nlm.nih.gov/pubmed/35657203
http://dx.doi.org/10.4274/tjh.galenos.2022.2022.0142

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9727716/
https://www.ncbi.nlm.nih.gov/pubmed/35657203
http://dx.doi.org/10.4274/tjh.galenos.2022.2022.0142

Ejemplares similares